Anagliptin vs Trelagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Anagliptin · Suiny
Marketed by Sanwa Kagaku Kenkyusho and partners
NCT01529541 · Phase 3 · completed
The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.
Next expected readout: March 2027 · NCT07442006 (registry estimate)
Reported efficacy
The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)
Result source: NCT01529528
Trelagliptin · Zafatek
Marketed by Teijin and partners
NCT01431807 · Phase 3 · completed
This was a single-group, open-label study with no randomization, blinding, or comparator arm, despite enrolling 680 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07073768 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)); Number of Participants Who Had One or More Treatment Emergent Adverse Event (TEAE) Before the Start of Study Drug Administration in Treatment Period II (Up to Week 12); Number of Participants Who Had One or More TEAE Occurred After 1st Dose of Trelagliptin 25 mg Tablet (Up to Week 54): Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089) (met)
Result source: NCT02512068
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Anagliptin | Trelagliptin |
|---|---|---|
| HbA1c, change | -0.5% vs 0.2%a−0.7 vs placeboNCT015295282 other results
| -0.7% vs 0.0%−0.7 vs placeboNCT025120684 other results
|
| Body weight, change (kg) | —Not posted · NCT01529528 | —Not posted · NCT03940183 |
| HbA1c below 7% | —Not posted · NCT01529528 | —Not posted · NCT03940183 |
| Fasting plasma glucose, change | —Not posted · NCT01529528 | -0.9 vs -0.0−0.9 vs placeboNCT025120683 other results
|
| 3-point MACE (% with event) | —Not posted · NCT01529528 | —Not posted · NCT03940183 |
HbA1c, change
- Anagliptin
- -0.5% vs 0.2%a−0.7 vs placeboNCT01529528
2 other results
- -0.5% vs 0.2% NCT01529528
- -0.8% vs -0.8% NCT01529541
- Trelagliptin
- -0.7% vs 0.0%−0.7 vs placeboNCT02512068
4 other results
- -0.7% vs 0.0% NCT02512068
- -0.6% vs -0.1% NCT02512068
- -0.5% vs 0.0% NCT02512068
- -0.2% vs 0.1% NCT02512068
Body weight, change (kg)
- Anagliptin
- —Not posted · NCT01529528
- Trelagliptin
- —Not posted · NCT03940183
HbA1c below 7%
- Anagliptin
- —Not posted · NCT01529528
- Trelagliptin
- —Not posted · NCT03940183
Fasting plasma glucose, change
- Anagliptin
- —Not posted · NCT01529528
- Trelagliptin
- -0.9 vs -0.0−0.9 vs placeboNCT02512068
3 other results
- -0.7 vs -0.2 NCT02512068
- -0.6 vs -0.1 NCT02512068
- -0.7 vs 0.1 NCT02512068
3-point MACE (% with event)
- Anagliptin
- —Not posted · NCT01529528
- Trelagliptin
- —Not posted · NCT03940183
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Anagliptin: 0 of 4 rows · Trelagliptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Anagliptin | Trelagliptin |
|---|---|---|
| Dropout rate | — | 21.8%25 mga NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more result0% NCT03014479 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | — | 14.5%25 mga NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more result0% NCT03014479 · Phase 4 · registry result, not featured evidence |
| Serious AEs | — | 41.8%25 mga NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more result1.8% NCT03014479 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | — | 25 mga nasopharyngitis 43.6% (placebo 33.3%) fall 21.8% (placebo 10.4%) hypoglycaemia 21.8% (placebo 14.6%) NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more resultviral upper respiratory tract infection 3.6% NCT03014479 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Trelagliptin
show 3 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Trelagliptin's landscape